NCT04729855Completed
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population
Source: ClinicalTrials.gov · Last updated 30 Apr 2025
Brief summary (registry, in English)
1. Determination of expression level of HOTTIP and EIF4EBP1(Eukaryotic translation initiation factor 4E-binding protein 1) . 2. Investigation of the SNP HOTTIP rs1859168 and it's association with CRC susceptibility. 3. Correlation of the expression of these genes with various stages of CRC to determine the prognostic value of each of them.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 60 (actual)
- First submitted
- 24 Jan 2021
- Start date
- 15 Apr 2022
- Primary completion date
- 20 May 2023
- Lead sponsor
- Esraa Hassan,MD
- Diseases
- Colorectal cancer
- NCT number
- NCT04729855
What you commit to
- Study type: Observational
- Participants enrolled: 60
- From 15 Apr 2022 to the primary completion date, 20 May 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- -patients who received any treatment.
Other illness
- Cases with other organ cancers.
- History of chemotherapy and radiotherapy.
- Systemic diseases such as renal failure, diabetes mellitus, and hypertension.
Who the study is looking for
- No sex predilection.
- Age (25-65 yr).
- Colorectal carcinoma confirmed by histopathological examination
Age in the registry: 25 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Assiut University Coordinator of this site? Confirm its status | Asyut | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.